QL0911
Phase 3Small molecule
Qilu Pharmaceutical Co., Ltd.QL0911 is one of 49 small molecule programs targeting Immune Thrombocytopenia. It is currently in Phase 3.
1
Indications
5
Total Trials
2
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
56 competitors in Immune Thrombocytopenia
#DrugCompanyPhaseTrials
1Promacta
GSKApproved
Rituxan
RocheApproved
Decadron
AAspen Global Incorporated
Approved
Plaquenil
Jazz PharmaceuticalsApproved
Oncovin
Eli LillyApproved
Rayos
RRoxane Laboratories
Approved
Imuran
LLegacy Health System
Approved
Vyvgart
ArgenxPhase 3
Doptelet
AAkarx
Phase 3
Wayrilz
GGenzyme, a Sanofi Company
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Thrombocytopenia2 trials
Immune Thrombocytopenia2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for QL0911. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details